Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)

Table 3 Change from baseline to EoT in MoCA test total score (SAF)

	Placebo	Mirabegron Total
Baseline, mean (SE)^a	26.8 (0.1)	26.9 (0.1)
EoT, mean (SE)^b	27.0 (0.1)	26.9 (0.1)
Adjusted change from baseline, mean (SE)	−0.1 (0.1)	−0.2 (0.1)
95% two-sided CI	(−0.4, 0.2)	(−0.4, 0.1)
p-value		0.471

CI confidence interval, EoT end of treatment, MoCA Montreal Cognitive Assessment, SAF safety analysis set, SE standard error
^aN = 440 for placebo and 443 for mirabegron total
^bN = 413 for placebo and 427 for mirabegron total

ISSN: 1471-2318